TY - JOUR
T1 - The EUROpean and chinese cardiac and renal Remote ischemic Preconditioning study (EURO-CRIPS)
T2 - Study design and Methods
AU - Moretti, Claudio
AU - Cavallero, Erika
AU - D'Ascenzo, Fabrizio
AU - Cerrato, Enrico
AU - Zoccai, Giuseppe Biondi
AU - Omedè, Pierluigi
AU - Presutti, Davide Giacomo
AU - Lefevre, Thierry
AU - Sanguineti, Francesca
AU - Picchi, Andrea
AU - Palazzuoli, Alberto
AU - Carini, Giovanni
AU - Giammaria, Massimo
AU - Ugo, Fabrizio
AU - Presbitero, Patrizia
AU - Chen, Shaoliang
AU - Lin, Song
AU - Sheiban, Imad
AU - Gaita, Fiorenzo
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Aims Contrast-induced nephropathy (CIN) and periprocedural myocardial infarction (PMI) represent frequent complications of percutaneous coronary intervention (PCI) and negatively impact subsequent length of hospitalization, costs of adjunctive diagnostic-therapeutic measures and mid-term cardiovascular events. The aim of the EURO-CRIPS trial is to test whether remote ischemic preconditioning (RIPC) may reduce the incidence of these complications and improve mid-term outcome. Methods This will be a double-blind, randomized, placebocontrolled multicentre study. Patients will be allocated 1:1 to RIPC or standard therapy if they were younger than 85 years old, with a renal clearance in the interval 30-60 ml/min/1.73m2 and candidate to PCI for all clinical indications except for primary PCI in ST segment elevation myocardial infarction (STEMI), unstable haemodynamic presentations or ongoing severe arrhythmias. Incidence of CIN will be the primary end point and the amount of periprocedural cardiac enzyme leakage will be the secondary end point. In addition, we will evaluate whether the preconditioned patients will have a reduction of MACCE at 6 months (major adverse cardiac and cerebrovascular event). Conclusion: The EURO-CRIPS Study will be the first largescale, multicentre clinical trial to test the role of RIPC in current clinical practice. The results of this randomized trial will provide important insights to optimize management strategy of patients undergoing PCI and to improve their outcome
AB - Aims Contrast-induced nephropathy (CIN) and periprocedural myocardial infarction (PMI) represent frequent complications of percutaneous coronary intervention (PCI) and negatively impact subsequent length of hospitalization, costs of adjunctive diagnostic-therapeutic measures and mid-term cardiovascular events. The aim of the EURO-CRIPS trial is to test whether remote ischemic preconditioning (RIPC) may reduce the incidence of these complications and improve mid-term outcome. Methods This will be a double-blind, randomized, placebocontrolled multicentre study. Patients will be allocated 1:1 to RIPC or standard therapy if they were younger than 85 years old, with a renal clearance in the interval 30-60 ml/min/1.73m2 and candidate to PCI for all clinical indications except for primary PCI in ST segment elevation myocardial infarction (STEMI), unstable haemodynamic presentations or ongoing severe arrhythmias. Incidence of CIN will be the primary end point and the amount of periprocedural cardiac enzyme leakage will be the secondary end point. In addition, we will evaluate whether the preconditioned patients will have a reduction of MACCE at 6 months (major adverse cardiac and cerebrovascular event). Conclusion: The EURO-CRIPS Study will be the first largescale, multicentre clinical trial to test the role of RIPC in current clinical practice. The results of this randomized trial will provide important insights to optimize management strategy of patients undergoing PCI and to improve their outcome
KW - Biochemical markers
KW - Coronary artery disease
KW - Renal disease
UR - http://www.scopus.com/inward/record.url?scp=84925844076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925844076&partnerID=8YFLogxK
U2 - 10.2459/JCM.0000000000000098
DO - 10.2459/JCM.0000000000000098
M3 - Article
C2 - 24859616
AN - SCOPUS:84925844076
VL - 16
SP - 246
EP - 252
JO - Journal of Cardiovascular Medicine
JF - Journal of Cardiovascular Medicine
SN - 1558-2027
IS - 3
ER -